Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

UBS's Michael Yee raised their price target on Gilead Sciences (NASDAQ: GILD) by 11.4% from $175 to $195 on 2026/10/31. The analyst maintained their Strong Buy rating on the stock.

Gilead Sciences reported its Q3 2026 earnings.

Yee said the company's good execution should be rewarded after it delivered a strong quarterly beat and raised its guidance based on HIV growth.

Earnings Report

For Q3 2026, Gilead Sciences reported:

• EPS of $2.55, which beat the Zacks Consensus Estimate of $2.17 and, by 3.2%, Q3 2025 $2.47.
• Revenue of $8.3B, which beat the Zacks Consensus Estimate by 6.21% and, by 13%, Q3 2025’s $7.77B.

For FY 2026, management guided:

• Loss per share of $1.20 to $0.85.
• Revenue of $31B to $31.3B.

Chairman & CEO Daniel O’Day commented: “Gilead delivered an exceptional Q3, with our strongest Y/Y base business growth in more than a decade, reflecting the strength, breadth and durability of our business.

“Our performance enabled us to raise our FY base business revenue guidance again this quarter, bringing the total increase to $1.6B since the start of 2026. 

“Our HIV business grew 18%, and HIV prevention sales nearly doubled Y/Y. 

“With multiple ongoing and potential launches across HIV and Oncology, important progress in Inflammation and a disciplined operating model, Gilead is well positioned for business growth and impact for patients.”